Myriad Genetics develops and sells molecular genetic tests for cancer, prenatal health, and mental health care. MYGN reports earnings on Wed, Nov 4, 2026. Analyst consensus is Hold, based on the latest ratings from 5 firms (1 buy, 3 hold, 1 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for MYGN are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MYGN is in one of them and how their past MYGN trades turned out.
Myriad Genetics is a molecular diagnostics company based in Salt Lake City, Utah. It develops and sells genetic tests that help assess disease risk, guide cancer treatment, and support prenatal and mental health care. Its main areas are oncology, women's health, and mental health, with tests such as MyRisk for hereditary cancer risk and BRACAnalysis CDx for selecting cancer therapy. Its customers include doctors, healthcare providers, patients, and biopharma companies.
